3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
3
lanreotide
3
Erlotinib Hydrochloride
3
surufatinib
2
gallium Ga 68 dotatate
2
dactolisib
2
Sunitinib
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Filgrastim
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tislelizumab
1
telotristat ethyl
1
telotristat
1
pertuzumab
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
folfirinox
1
famitinib
1
entinostat
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Temozolomide
1
Surveys and Questionnaires
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Somatostatin
×
NET
×
Clear all
NCT01755182
2016-05-06
LOTUS
National Cancer Institute, Naples
Phase 3
Terminated
1 enrolled